SELLAS Life Sciences Group (SELLAS Life Sciences Group) Cash-to-Debt : 2.79 (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. SELLAS Life Sciences Group's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.79.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, SELLAS Life Sciences Group could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for SELLAS Life Sciences Group's Cash-to-Debt or its related term are showing as below:

SLS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21 Med: 12.2 Max: No Debt
Current: 2.79

During the past 13 years, SELLAS Life Sciences Group's highest Cash to Debt Ratio was No Debt. The lowest was 0.21. And the median was 12.20.

SLS's Cash-to-Debt is ranked worse than
62.57% of 1539 companies
in the Biotechnology industry
Industry Median: 6.49 vs SLS: 2.79

SELLAS Life Sciences Group Cash-to-Debt Historical Data

The historical data trend for SELLAS Life Sciences Group's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

SELLAS Life Sciences Group Cash-to-Debt Chart

SELLAS Life Sciences Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

33.54

35.62

26.43

18.12

2.79

SELLAS Life Sciences Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															18.12	28.15	18.43	6.16	2.79

Competitive Comparison of SELLAS Life Sciences Group's Cash-to-Debt

For the Biotechnology subindustry, SELLAS Life Sciences Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SELLAS Life Sciences Group's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Cash-to-Debt falls into.

SELLAS Life Sciences Group Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

SELLAS Life Sciences Group's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.53	/	(0.446	+	0.46)
	=	2.79

SELLAS Life Sciences Group's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.53	/	(0.446	+	0.46)
	=	2.79

SELLAS Life Sciences Group (NAS:SLS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

SELLAS Life Sciences Group Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

SELLAS Life Sciences Group (SELLAS Life Sciences Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (NAS:SLS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

RXK3:Germany

Address

7 Times Square, Suite 2503, New York, NY, USA, 10036

Website

https://www.sellaslifesciences.com

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Executives

Angelos M. Stergiou	director, officer: President and CEO	C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, SUITE 380, SAN RAMON CA 94583
Barbara A Wood	officer: EVP, Gen. Counsel, Corp. Sec.	58 S SERVICE RD, MELVILLE NY 11747
John Thomas Burns	officer: VP, Finance & Corp Controller	16760 SW UPPER BOONES FERRY RD, SUITE 101, PORTLAND X1 97224
Katherine Bach Kalin	director	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Robert Francomano	officer: Chief Commercial Officer	C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 11TH FLOOR, NEW YORK NY 10022
Nicholas J. Sarlis	officer: Chief Medical Officer and SVP	C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, STE. 380, SAN RAMON CA 94583
Stephen F Ghiglieri	director	C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Jane Wasman	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David A Scheinberg	director	325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
John Varian	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely Ii Fund`	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely I Fund	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Equilibria Capital Management Ltd	10 percent owner	O'HARA HOUSE, ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Ii Sac Fund Ltd-eqc Biotech Sely Iii Fund	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08